Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling

Adam R. Williams; Barry Trachtenberg; Darcy L. Velazquez; Ian McNiece; Peter Altman; Didier Rouy; Adam M. Mendizabal; Pradip M. Pattany; Gustavo A. Lopera; Joel Fishman; Juan P. Zambrano; Alan W. Heldman; Joshua M. Hare

doi:10.1161/CIRCRESAHA.111.242610

Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling

Adam R. Williams, Barry Trachtenberg, Darcy L. Velazquez, Ian McNiece, Peter Altman, Didier Rouy, Adam M. Mendizabal, Pradip M. Pattany, Gustavo A. Lopera, Joel Fishman, Juan P. Zambrano, Alan W. Heldman, Joshua M. Hare

Research output: Contribution to journal › Article › peer-review

240 Scopus citations

Abstract

Rationale: Transcatheter, intramyocardial injections of bone marrow-derived cell therapy produces reverse remodeling in large animal models of ischemic cardiomyopathy. Objective: We used cardiac MRI (CMR) in patients with left ventricular (LV) dysfunction related to remote myocardial infarction (MI) to test the hypothesis that bone marrow progenitor cell injection causes functional recovery of scarred myocardium and reverse remodeling. Methods and results: Eight patients (aged 57.2±13.3 years) received transendocardial, intramyocardial injection of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in LV scar and border zone. All patients tolerated the procedure with no serious adverse events. CMR at 1 year demonstrated a decrease in end diastolic volume (208.7±20.4 versus 167.4±7.32 mL; P=0.03), a trend toward decreased end systolic volume (142.4±16.5 versus 107.6±7.4 mL; P=0.06), decreased infarct size (P

Original language	English (US)
Pages (from-to)	792-796
Number of pages	5
Journal	Circulation Research
Volume	108
Issue number	7
DOIs	https://doi.org/10.1161/CIRCRESAHA.111.242610
State	Published - Apr 1 2011
Externally published	Yes

Keywords

bone marrow
heart failure
reverse remodeling
stem cells

ASJC Scopus subject areas

Physiology
Cardiology and Cardiovascular Medicine

Access to Document

10.1161/CIRCRESAHA.111.242610

Cite this

Williams, A. R., Trachtenberg, B., Velazquez, D. L., McNiece, I., Altman, P., Rouy, D., Mendizabal, A. M., Pattany, P. M., Lopera, G. A., Fishman, J., Zambrano, J. P., Heldman, A. W., & Hare, J. M. (2011). Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circulation Research, 108(7), 792-796. https://doi.org/10.1161/CIRCRESAHA.111.242610

Williams, AR, Trachtenberg, B, Velazquez, DL, McNiece, I, Altman, P, Rouy, D, Mendizabal, AM, Pattany, PM, Lopera, GA, Fishman, J, Zambrano, JP, Heldman, AW & Hare, JM 2011, 'Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling', Circulation Research, vol. 108, no. 7, pp. 792-796. https://doi.org/10.1161/CIRCRESAHA.111.242610

@article{8150ec197f824325a1915842c4d0873c,

title = "Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling",

abstract = "Rationale: Transcatheter, intramyocardial injections of bone marrow-derived cell therapy produces reverse remodeling in large animal models of ischemic cardiomyopathy. Objective: We used cardiac MRI (CMR) in patients with left ventricular (LV) dysfunction related to remote myocardial infarction (MI) to test the hypothesis that bone marrow progenitor cell injection causes functional recovery of scarred myocardium and reverse remodeling. Methods and results: Eight patients (aged 57.2±13.3 years) received transendocardial, intramyocardial injection of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in LV scar and border zone. All patients tolerated the procedure with no serious adverse events. CMR at 1 year demonstrated a decrease in end diastolic volume (208.7±20.4 versus 167.4±7.32 mL; P=0.03), a trend toward decreased end systolic volume (142.4±16.5 versus 107.6±7.4 mL; P=0.06), decreased infarct size (P",

keywords = "bone marrow, heart failure, reverse remodeling, stem cells",

author = "Williams, {Adam R.} and Barry Trachtenberg and Velazquez, {Darcy L.} and Ian McNiece and Peter Altman and Didier Rouy and Mendizabal, {Adam M.} and Pattany, {Pradip M.} and Lopera, {Gustavo A.} and Joel Fishman and Zambrano, {Juan P.} and Heldman, {Alan W.} and Hare, {Joshua M.}",

year = "2011",

month = apr,

day = "1",

doi = "10.1161/CIRCRESAHA.111.242610",

language = "English (US)",

volume = "108",

pages = "792--796",

journal = "Circulation Research",

issn = "0009-7330",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - Intramyocardial stem cell injection in patients with ischemic cardiomyopathy

T2 - Functional recovery and reverse remodeling

AU - Williams, Adam R.

AU - Trachtenberg, Barry

AU - Velazquez, Darcy L.

AU - McNiece, Ian

AU - Altman, Peter

AU - Rouy, Didier

AU - Mendizabal, Adam M.

AU - Pattany, Pradip M.

AU - Lopera, Gustavo A.

AU - Fishman, Joel

AU - Zambrano, Juan P.

AU - Heldman, Alan W.

AU - Hare, Joshua M.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Rationale: Transcatheter, intramyocardial injections of bone marrow-derived cell therapy produces reverse remodeling in large animal models of ischemic cardiomyopathy. Objective: We used cardiac MRI (CMR) in patients with left ventricular (LV) dysfunction related to remote myocardial infarction (MI) to test the hypothesis that bone marrow progenitor cell injection causes functional recovery of scarred myocardium and reverse remodeling. Methods and results: Eight patients (aged 57.2±13.3 years) received transendocardial, intramyocardial injection of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in LV scar and border zone. All patients tolerated the procedure with no serious adverse events. CMR at 1 year demonstrated a decrease in end diastolic volume (208.7±20.4 versus 167.4±7.32 mL; P=0.03), a trend toward decreased end systolic volume (142.4±16.5 versus 107.6±7.4 mL; P=0.06), decreased infarct size (P

AB - Rationale: Transcatheter, intramyocardial injections of bone marrow-derived cell therapy produces reverse remodeling in large animal models of ischemic cardiomyopathy. Objective: We used cardiac MRI (CMR) in patients with left ventricular (LV) dysfunction related to remote myocardial infarction (MI) to test the hypothesis that bone marrow progenitor cell injection causes functional recovery of scarred myocardium and reverse remodeling. Methods and results: Eight patients (aged 57.2±13.3 years) received transendocardial, intramyocardial injection of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in LV scar and border zone. All patients tolerated the procedure with no serious adverse events. CMR at 1 year demonstrated a decrease in end diastolic volume (208.7±20.4 versus 167.4±7.32 mL; P=0.03), a trend toward decreased end systolic volume (142.4±16.5 versus 107.6±7.4 mL; P=0.06), decreased infarct size (P

KW - bone marrow

KW - heart failure

KW - reverse remodeling

KW - stem cells

UR - http://www.scopus.com/inward/record.url?scp=79954928346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954928346&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.111.242610

DO - 10.1161/CIRCRESAHA.111.242610

M3 - Article

C2 - 21415390

AN - SCOPUS:79954928346

SN - 0009-7330

VL - 108

SP - 792

EP - 796

JO - Circulation Research

JF - Circulation Research

IS - 7

ER -

Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this